hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06349772, orgStudyIdInfo id: FY2024-203, briefTitle: Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2025-04-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Texas Tech University Health Sciences Center, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two extended local anesthesia strategies currently approved by FDA and on the market for post-surgical pain control. The investigators plan on randomizing study participants to either Exparel or Zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively both in the hospital and at home. The investigators will measure the outcome of two drugs, Zynrelief, and Exparel on postoperative pain score -using the NRS pin score up to 72 hours after surgery. The total opioid use will be recorded in forms that will be used to measure pain score and total opioid use and will be collected to the Excel sheet. The cost of the drug will be calculated for internal use for Hospital purpose only., conditionsModule conditions: Post Operative Pain, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomizing study participants to either Exparel or Zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 130, type: ESTIMATED, armsInterventionsModule interventions name: Zynrelef, interventions name: Exparel, outcomesModule primaryOutcomes measure: postoperative pain score, secondaryOutcomes measure: Total postoperative opioid use, secondaryOutcomes measure: Proportion of total rescue medication use, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349759, orgStudyIdInfo id: OPI-NYXDLD-302, briefTitle: Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances, acronym: LYNX-2, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2025-11, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Ocuphire Pharma, Inc., class: INDUSTRY, collaborators name: Viatris Inc., descriptionModule briefSummary: Safety and efficacy of 0.75% Phentolamine Ophthalmic Solution to improve mesopic low contrast visual acuity in subjects with post-refractive surgery visual disturbances., conditionsModule conditions: Mesopic Vision, conditions: Night Vision Loss, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, interventions name: Placebo, outcomesModule primaryOutcomes measure: Percent of subjects with an increase of at least 15 ETDRS letters read (≥ 3 lines) in the study eye in mLCVA compared to Baseline (Day 1 pre-dose) at Day 15, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: United States, California, status: RECRUITING, city: Newport Beach, state: California, zip: 92663, country: United States, geoPoint lat: 33.61891, lon: -117.92895, locations facility: United States, North Carolina, status: RECRUITING, city: Garner, state: North Carolina, zip: 27529, country: United States, geoPoint lat: 35.71126, lon: -78.61417, locations facility: United States, Rhode Island, status: RECRUITING, city: Warwick, state: Rhode Island, zip: 02888, country: United States, geoPoint lat: 41.7001, lon: -71.41617, hasResults: False
protocolSection identificationModule nctId: NCT06349746, orgStudyIdInfo id: collage of physical therapy, briefTitle: Cervical Unilateral Antero-posterior Mobilization and Thoracic Central Postro-anterior Mobilization in Treatment of Shoulder Impingement Syndrome, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Egyptian Chinese University, class: OTHER, collaborators name: Benha University, descriptionModule briefSummary: Shoulder impingement syndrome (SIS) is a complex, multi-factorial problem that is treated with a variety of different conservative options. The conservative option that has shown effectiveness is manual therapy of the cervical and thoracic spine, conditionsModule conditions: Shoulder Impingement, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: this study will be conducted to compare one group receiving selected therapeutic exercises and other group recieve cervical and thoracic mobilization added to selected therapeutic exercise Program on pain intensity, Pain-free shoulder flexion and scaption active ROM, muscle strength of external rotator and abductors, shoulder functional status in patients with Shoulder Impingement Syndrome., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: patients and outcomes assessor will be masked about the grouping of the study, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: therapeutic exercises, interventions name: mobilization exercise, outcomesModule primaryOutcomes measure: pain intensity, primaryOutcomes measure: shoulder flexion and abduction range of motion, primaryOutcomes measure: muscle strength, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349733, orgStudyIdInfo id: MR-37-23-008382, briefTitle: Effectiveness of Botulinum Toxin A in Preventing Scar Formation and Initial Exploration of "Optimal Concentration", statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-03-23, primaryCompletionDateStruct date: 2023-11-10, completionDateStruct date: 2024-04-10, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Qilu Hospital of Shandong University, class: OTHER, descriptionModule briefSummary: Each year, millions of burn, trauma, or surgical patients worldwide suffer from scarring that severely affects their quality of life and social functioning. In order to prevent and treat diseases related to abnormal scar hyperplasia, clinicians and researchers have adopted various methods, such as scar grinding, surgical resection, drug injection in scar tissue, cryotherapy, laser and so on. However, these methods can not effectively inhibit the abnormal proliferation of scars and improve the adverse effects of existing scars on patients. To date, there is no accepted gold standard for the effective treatment and improvement of abnormal scar tissue., conditionsModule conditions: Scar, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ACTUAL, armsInterventionsModule interventions name: Botulinum toxin type A, outcomesModule primaryOutcomes measure: The modified Stony Brook Scar Evaluation Scale, secondaryOutcomes measure: Patient satisfaction, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 65 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Qilu Hospital of Shandong University Dezhou Hospital, city: Dezhou, state: Shandong, zip: 253000, country: China, geoPoint lat: 37.45127, lon: 116.31046, hasResults: False
protocolSection identificationModule nctId: NCT06349720, orgStudyIdInfo id: KF-2023-355, briefTitle: Investigating Long-term Health Effects and Complications in COVID-19 Recoveries, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-07, primaryCompletionDateStruct date: 2024-06-07, completionDateStruct date: 2024-06-07, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Zhaohui Tong, class: OTHER, descriptionModule briefSummary: Clarify the incidence of functional impairments in cured COVID-19 patients and identify influencing factors. Build a multi-omics database for COVID-19 patients in the recovery period to elucidate the biological biomarkers and targets associated with functional impairments. Comprehensive exploration of the long-term prognosis, complications, sequelae, and risk factors of COVID-19 patients after Omicron infection, as well as their immune characteristics. Compare the impact of different strains of the COVID-19 virus on prognosis and immune response. Develop comprehensive rehabilitation intervention strategies for COVID-19 patients with functional impairments and evaluate the impact of different intervention methods on their prognosis. Based on clinical data, multi-omics data, and precise rehabilitation assessment data, construct predictive models for prognosis and rehabilitation effectiveness in COVID-19, providing scientific evidence for the implementation of effective COVID-19 rehabilitation measures., conditionsModule conditions: COVID-19 Patients, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 17000, type: ESTIMATED, armsInterventionsModule interventions name: respiratory rehabilitation, outcomesModule primaryOutcomes measure: Immunological characteristics associated with functional impairments in COVID-19 convalescent patients, primaryOutcomes measure: Changes in laboratory examination indicators, primaryOutcomes measure: High-resolution CT of the chest, primaryOutcomes measure: Pulmonary function test, primaryOutcomes measure: Multi-omics changes and characteristics associated with functional impairments in COVID-19 convalescent patients, primaryOutcomes measure: Inflammatory factors related to body dysfunction in COVID-19 rehabilitation patients, primaryOutcomes measure: Regular rehabilitation assessment following respiratory rehabilitation intervention in COVID-19 patients, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 120 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Institute of Respiratory Medicine, status: RECRUITING, city: Beijing, state: Beijing, zip: 100027, country: China, contacts name: Zhaohui Tong, Dr, role: CONTACT, phone: +86 010 8523 1000, email: 13910930309@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06349707, orgStudyIdInfo id: 2023PI112, briefTitle: Multiplex PCR for Severe Respiratory Infections During the COVID-19 Pandemic, acronym: VirCoV+, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Central Hospital, Nancy, France, class: OTHER, descriptionModule briefSummary: The hypothesis was that a retrospective investigation of the molecular virological tests in a University hospital could be informative, with the aim to identify non-COVID-19 respiratory viruses during the circulation of SARS-CoV-2, according to systematic population data for public health knowledge., conditionsModule conditions: Viral Pneumonia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: ECOLOGIC_OR_COMMUNITY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: other: Observational, outcomesModule primaryOutcomes measure: Occurrence of positive viral PCR assays (not COVID-19) from hospitalizations for respiratory infections., secondaryOutcomes measure: Real-life features of patients in Intensive care (from the whole population - Outcome 1) with positive viral PCR during infectious pneumonia., eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Schvoerer, city: Vandoeuvre Les Nancy, zip: 54511, country: France, geoPoint lat: 48.65, lon: 6.18333, hasResults: False
protocolSection identificationModule nctId: NCT06349694, orgStudyIdInfo id: PamukkaleU.ftr-NYıldız-001, briefTitle: Comparison of the Efficacy of Transcutaneos Nerve Stimulations in Women With Idiopathic Overactive Bladder, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-22, primaryCompletionDateStruct date: 2025-01-31, completionDateStruct date: 2025-02-28, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Pamukkale University, class: OTHER, descriptionModule briefSummary: Our study is the first prospective randomized controlled trial that compares the effectiveness of transcutaneous medial plantar nerve stimulation (T-MPNS) and transcutaneous tibial nerve stimulation (TTNS) added to bladder training (BT) in women with idiopathic overactive bladder (OAB). İn this study, we aimed to assess the efficacy of T-MPNS and TTNS added to BT on quality of life (QoL) and clinical parameters asssociated with idiopathic OAB. In addition, preparation time for stimulation, treatment satisfaction and discomfort levels of the patients were evaluated.The main questions we aim to answer are:Is T-MPNS as effective as TTNS in the treatment of idiopathic OAB? For this purpose, we planned to compare transcutaneous applications of the tibial and plantar medial nerve in women with idiopathic OAB. 60 women with OAB will be randomized to 3 groups by using random number generator: BT program alone to Group 1 (n=20), BT plus T-MPNS to Group 2 (n=20), BT plus TTNS to Group 3 (n=20) will be applied., conditionsModule conditions: Urinary Bladder, Overactive, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Transcutaneous MPN stimulation (T-MPNS), interventions name: Transcutaneous tibial nerve stimulation (TTNS), interventions name: BT (Control group), outcomesModule primaryOutcomes measure: Improvement in incontinence episodes (positive response rate), secondaryOutcomes measure: The severity of incontinence, secondaryOutcomes measure: Symptom severity, secondaryOutcomes measure: Frequency of voiding, nocturia, number of pads, secondaryOutcomes measure: Quality of life (IIQ7), secondaryOutcomes measure: The Hospital Anxiety and Depression Scale (HAD), secondaryOutcomes measure: FSFI, secondaryOutcomes measure: Cure-improvement rates, secondaryOutcomes measure: Treatment satisfaction, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pamukkale University, city: Denizli, country: Turkey, geoPoint lat: 37.77417, lon: 29.0875, hasResults: False
protocolSection identificationModule nctId: NCT06349681, orgStudyIdInfo id: CONOXBird, briefTitle: Describe Relations Between qCON and qNOX Indicies During Propofol-Remifentanil General Anesthesia, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2024-10-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: University of Padova, class: OTHER, descriptionModule briefSummary: CONOX is a neuromonitoring EEG- device for sedation (qCON) and analgesia (qNOX) monitoring during general anesthesia.It is unknown on how the indicies can differentiate themselves so aim of this study is to determine the relationship bewtween the 2 indicies., conditionsModule conditions: Anesthesia Brain Monitoring, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 14, type: ESTIMATED, outcomesModule primaryOutcomes measure: Correlation between qCON and qNOX, secondaryOutcomes measure: Correlation between qCON and concentrations of Propofol(CeP), secondaryOutcomes measure: Correlation between qNOX and concentrations of Remifentanil (CeR), eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Treviso Regional Hospital, status: RECRUITING, city: Treviso, state: TV, zip: 31100, country: Italy, contacts name: Federico Linassi, role: CONTACT, email: federico.linassi@gmail.com, geoPoint lat: 45.66673, lon: 12.2416, hasResults: False
protocolSection identificationModule nctId: NCT06349655, orgStudyIdInfo id: 2023-KY-0865-001, briefTitle: The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-12-05, primaryCompletionDateStruct date: 2024-01-15, completionDateStruct date: 2024-03-10, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital of Zhengzhou University, class: OTHER, collaborators name: Henan Provincial Chest Hospital, collaborators name: The Affiliated Infectious Disease Hospital of Zhengzhou University, collaborators name: The Fifth People's Hospital of Anyang, collaborators name: Shangqiu Municipal Hospital, collaborators name: Nanyang Central Hospital, collaborators name: Luoyang Central Hospital, collaborators name: Guangshan County People's Hospital, collaborators name: Fengqiu County People's Hospital, descriptionModule briefSummary: To establish a real-world clinical cohort and database of Azvudine in the treatment of SARS-CoV-2 infection, and to provide stable and reliable evidence for the clinical efficacy and safety evaluation of azvudine in the treatment of SARS-CoV-2 infection., conditionsModule conditions: COVID-19, conditions: Azvudine, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 32864, type: ACTUAL, armsInterventionsModule interventions name: Azvudine, interventions name: Paxlovid, outcomesModule primaryOutcomes measure: All-cause death, secondaryOutcomes measure: Composite disease progression, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Zhengzhou University, city: Zhengzhou, state: Henan, zip: 450052, country: China, geoPoint lat: 34.75778, lon: 113.64861, hasResults: False
protocolSection identificationModule nctId: NCT06349629, orgStudyIdInfo id: 20240401, briefTitle: The Clinical Study of 3D-printed Magnesium Alloy Prosthesis With Controllable Degradation Rate in the Repair of Periarticular Bone Defects, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2027-01-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Peking University Third Hospital, class: OTHER, descriptionModule briefSummary: Perimarticular fracture bone defect is a common and complicated clinical disease. The current treatment for this type of injury is anatomical reduction of the fracture, where the bone defect is filled with artificial, autologous or allogeneic bone in granular form, and then fixed with plates and screws. However, these bone filler materials exist in a loose accumulation state and cannot form an effective overall support force for the joint. The applicant realized three dimensional (3D) printing of WE43 magnesium alloy with personalized design and porous overall structure, and developed high-temperature heat treatment technology to slow its degradation, which effectively realized the dual stability of degradation rate of magnesium alloy support body and overall structure during the bone repair period. This project will optimize the design of 3D printed WE43 magnesium alloy full-structure in-bone support, and establish a metamaterial pore structure design platform that regulates the physical properties and degradation behavior of porous implants. Fracture from proximal humerus, distal radius and tibial plateau, conditionsModule conditions: Degradation of Magnesium Alloy Prosthesis and New Bone Regeneration, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: 3D printed WE43 magnesium alloy, outcomesModule primaryOutcomes measure: Detection of Magnesium alloy metabolism, primaryOutcomes measure: Degradation of 3D printed magnesium alloy prosthesis, primaryOutcomes measure: New bone regeneration, primaryOutcomes measure: Evaluation of shoulder joint function, primaryOutcomes measure: Evaluation of wrist joint function, primaryOutcomes measure: Evaluation of knee joint function, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University Third Hospital, status: RECRUITING, city: Beijing, state: Haidian, country: China, contacts name: Bingchuan Liu, role: CONTACT, phone: +86 18310188678, email: liubc@bjmu.edu.cn, geoPoint lat: 39.9075, lon: 116.39723, locations facility: Peking University Third Hospita, status: RECRUITING, city: Beijing, zip: 100083, country: China, contacts name: Yun Tian, M.D, role: CONTACT, phone: +8613701053505, email: tiany@bjmu.edu.cn, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False